Astegolimab

Highest phase reached
Phase 3
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 3
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Astegolimab
www.ebi.ac.uk

  • amg 282
  • AMG 282
  • AMG-282
  • amg282
  • AMG282
  • astegolimab
  • Astegolimab
  • astegolimab [INN]
  • ASTEGOLIMAB [USAN]
  • Astegolimab [WHO-DD]
  • astegolimab inn
  • astegolimab usan
  • astegolimab who dd
  • human mab that inhibits the binding of il 33 nf hev to il 1 receptor like 1
  • HUMAN MAB THAT INHIBITS THE BINDING OF IL-33 (NF-HEV) TO IL-1 RECEPTOR-LIKE 1
  • immunoglobulin g2 anti human interleukin 33 receptor human monoclonal mstt1041a gamma 2 chain disulfide with human monoclonal mstt1041a kappa chain dimer
  • IMMUNOGLOBULIN G2, ANTI-(HUMAN INTERLEUKIN-33 RECEPTOR) (HUMAN MONOCLONAL MSTT1041A .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MSTT1041A .KAPPA.-CHAIN, DIMER
  • immunoglobulin gx kappa anti homo sapiens interleukin 1 receptor like 1 protein st2 ec 3 2 2 6 homo sapiens monoclonal antibody gamma 2 heavy chain homo sapiens 1 447 homo sapiens vh ighv5 51 01 96 ighd ighj6 01 94 8 8 14 1 121 homo sapiens ighg2 01 122 447 135 214 disulfide with kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv1 33 01 98 igkj4 01 6 3 9 1 107 homo sapiens igkc 01 108 214 dimer 223 223 224 224 227 227 230 230 tetrakisdisulfide
  • IMMUNOGLOBULIN GX-KAPPA, ANTI-(HOMO SAPIENS INTERLEUKIN-1 RECEPTOR-LIKE 1 (PROTEIN ST2, EC=3.2.2.6)) HOMO SAPIENS MONOCLONAL ANTIBODY.GAMMA.2 HEAVY CHAIN HOMO SAPIENS (1-447) (HOMO SAPIENS VH (IGHV5-51*01 (96%) (IGHD)-IGHJ6*01 (94%)) (8.8.14) (1-121)-HOMO SAPIENS IGHG2*01 (122-447)) (135-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HOMO SAPIENS (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-33*01 (98%) IGKJ4*01)(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (223-223'':224-224'':227-227'':230-230'')-TETRAKISDISULFIDE
  • mstt 1041a
  • MSTT-1041A
  • mstt1041a
  • Mstt1041a
  • MSTT1041A
  • rg 6149

And 5 more, listed on the interactive page.

CAS registry numbers
  • 2173054-79-8
ChEMBL ID
CHEMBL4594385
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 27TW751DTH

First in class
No
Orphan designation
No

Drug name stem
-mab

  • Mechanism
    IL-33 receptor (ST2) inhibitor
    Action type
    Inhibitor
    Target
    IL-33 receptor (ST2)
    Protein identifier
    Q01638
  • Mechanism
    IL-33 receptor (ST2) inhibitor
    Action type
    Inhibitor
    Target
    IL-33 receptor (ST2)
    Protein identifier
    Q9NPH3

Open Targets mechanisms

  • Mechanism
    IL-33 receptor (ST2) inhibitor
    Action type
    Inhibitor
    Target
    IL-33 receptor (ST2)

  • Condition
    Dermatitis, Atopic
    Highest recorded phase
    2
    Condition identifier
    EFO:0000274
    Subject identifier
    D003876
  • Condition
    Pulmonary Disease, Chronic Obstructive
    Highest recorded phase
    3
    Condition identifier
    EFO:0000341
    Subject identifier
    D029424
  • Condition
    Asthma
    Highest recorded phase
    2
    Condition identifier
    MONDO:0004979
    Subject identifier
    D001249
  • Condition
    Severe Acute Respiratory Syndrome
    Highest recorded phase
    2
    Condition identifier
    MONDO:0100096
    Subject identifier
    D045169

  • Condition identifier
    EFO_0000274
    Highest recorded phase
    2
  • Condition identifier
    EFO_0000341
    Highest recorded phase
    3
  • Condition identifier
    EFO_1002029
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0004979
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0004980
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005002
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0100096
    Highest recorded phase
    2

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Disulfide bridges location (isoform A)
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 135-214' $ 135''-214''' $ 148-204 $ 148''-204'' $ 223-223'' $ 224-224'' $ 227-227'' $ 230-230'' $ 261-321 $ 261''-321'' $ 367-425 $ 3670''-425''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Glycosylation sites (N)
    Sequence
    Asn-297 $ Asn-297''''
  • Component
    Glycosylation sites (N)
    Sequence
    Asn-297 $ Asn-297''

Related records

Trials (10)

In development for (4)

Targets (2)